	US 11,752,164 B2
	Bortezomib compositions
Srikanth Sundaram, Somerset, NJ (US); and Daniel Charles Stewart, Queensbury, NY (US)
Assigned to MAIA PHARMACEUTICALS, INC., Princeton, NJ (US)
Filed by MAIA Pharmaceuticals, Inc., Princeton, NJ (US)
Filed on Mar. 22, 2023, as Appl. No. 18/188,384.
Application 18/188,384 is a continuation of application No. 17/934,901, filed on Sep. 23, 2022, granted, now 11,679,119.
Claims priority of provisional application 63/248,314, filed on Sep. 24, 2021.
Prior Publication US 2023/0218647 A1, Jul. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/69 (2006.01); A61K 9/08 (2006.01); A61K 47/12 (2006.01); A61K 47/20 (2006.01); A61K 47/26 (2006.01); A61P 35/00 (2006.01); A61K 47/02 (2006.01); A61K 9/00 (2006.01); A61K 31/198 (2006.01); A61K 31/4439 (2006.01); A61K 31/573 (2006.01); A61K 45/06 (2006.01); A61K 47/18 (2017.01); A61K 47/40 (2006.01)

CPC A61K 31/69 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 31/198 (2013.01); A61K 31/4439 (2013.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); A61K 47/20 (2013.01); A61K 47/26 (2013.01); A61K 47/40 (2013.01); A61P 35/00 (2018.01)]

12 Claims

1. A method for administering bortezomib to a patient in need thereof comprising parenterally administering to the patient a liquid, ready-to-use aqueous composition consisting of about 1 mg/mL bortezomib, about 10 mg/mL mannitol, about 20 mg/mL dimethyl sulfoxide, about 0.82 mg/mL sodium acetate, water and, optionally, hydrochloric acid, sodium hydroxide, or a combination thereof, wherein the pH of the ready-to-use composition is about 5 to about 6.